Progress in cardiovascular biology: PPAR for the course.
Studies on mice lacking the peroxisome proliferator-activated receptor (PPAR) suggest that PPAR ligands reduce lipid accumulation in foamy macrophages, and may target other receptors. These findings warrant an in-depth investigation into the gene regulatory mechanisms of PPAR ligands, which are currently being developed as drugs to treat atherosclerosis and diabetes.
Lazar
M A
MA
Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine and Genetics and The Penn Diabetes Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. lazar@mail.med.upenn.edu
D000818:Animals; D018955:CD36 Antigens / Q000378:metabolism; D002320:Cardiovascular Physiological Phenomena; D005487:Foam Cells / Q000378:metabolism; D006801:Humans; D008024:Ligands; D008077:Lipoproteins, LDL / Q000378:metabolism; D051379:Mice; D018345:Mice, Knockout; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism / Q000502:physiology*
D018955:CD36 Antigens; D008024:Ligands; D008077:Lipoproteins, LDL; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors